Disc Medicine reports Phase 2 DISC-3405 data from RESTORE-PV
Disc Medicine said initial Phase 2 RESTORE-PV data showed DISC-3405 controlled hematocrit and markedly reduced phlebotomy events.
Key Highlights:Original SEC Filing: Disc Medicine, Inc. [ IRON ] - 8-K - Sep. 10, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider verifying…